DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2020年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3763

Title: Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma.
Other Titles: 10cm以上の巨大肝細胞癌に対する、ゼラチンスポンジによる肝動脈塞栓術 (bland TAE) と、Lipiodolと抗癌剤による肝動脈化学塞栓術 (TACE) の併用法の治療効果
Authors: Hidaka, Teruyuki
Anai, Hiroshi
Sakaguchi, Hiroshi
Sueyoshi, Satoru
Tanaka, Toshihiro
Yamamoto, Kiyosei
Morimoto, Kengo
Nishiofuku, Hideyuki
Maeda, Shinsaku
Nagata, Takeshi
Kichikawa, Kimihiko
Keywords: huge hepatocellular carcinoma
transarterial chemoembolization
bland embolization
Issue Date: 7-Feb-2020
Publisher: Taylor & Francis
Citation: Minimally invasive therapy and allied technologies. Online ahead of print (2020 Feb 7)
Abstract: Introduction: To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC).Material and methods: Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed.Results: The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively.Conclusion: Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.
Description: 博士(医学)・乙第1462号・令和2年6月30日
© 2020 Society of Medical Innovation and Technology
This is a post-peer-review, pre-copyedit version of an article published in Minimally invasive therapy and allied technologies. The final authenticated version is available online at: https://doi.org/10.1080/13645706.2020.1725580.
発行元が定める登録猶予期間終了の後、本文を登録予定(2021.02)
URI: http://hdl.handle.net/10564/3763
ISSN: 13645706
Academic Degrees and number: 24601B1462
Degree-granting date: 2020-06-30
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2020年度

Files in This Item:

File Description SizeFormat
01乙1462本文の要旨.pdf乙1462本文の要旨1.51 MBAdobe PDFView/Open
02乙1462審査要旨.pdf乙1462審査要旨3.48 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback